OTCMKTS : $OCEL 📋 Organicell Activates COPD Trial at Mayo Clinic! Benzinga Digital Content Studio

Digital Asset Direct by Organicell Regenerative Medicine, Inc.

Detroit, Michigan | November 16, 2022 01:20 PM Eastern Standard Time

Phase I/II clinical trials will be held at Mayo Clinic in Phoenix, Arizona to study the safety and efficacy of Organicell Regenerative Medicine, Inc.'s (OTCMKTS: OCEL) drug, Zofin, in benefiting sufferers of Chronic Obstructive Pulmonary Disease (COPD)! 🗒 Organicell Regenerative Medicine, Inc., is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases & the provision of other related services. Visit Organicell here 👉 https://organicell.com/

Contact Details

Organicell Investor Relations

IR@organicell.com

Company Website

https://organicell.com/